Method for preparing monoclonal antibody in vivo and application
Through the hybridization and abdominal pretreatment technology of BALB/c mice and PT mice, combined with the ammonium sulfate salting purification step, the problem of high strain limitation and purification costs in the production of monoclonal antibodies in vivo is solved, achieving high efficiency and low cost The preparation and purification of antibodies are suitable for clinical trials and pharmaceutical production.
Patent Information
- Application Number
- CN202411021914.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, monoclonal antibodies have problems such as limited strain, low ascites, high cost of traditional purification processes and complex processes in the in vivo production process, resulting in high clinical trials and medical costs, making it difficult to achieve large-scale production.
BALB/c mice were used to hybridize with PT mice, and the accused hybridoma cell suspension was injected through paraffin and phytane pretreatment, and accumulated hybridoma cell suspension was obtained to obtain high concentration of monoclonal antibody ascites, and the ammonium sulfate salting was analyzed, filtered and concentrated. and the purification step of the displacement buffer to improve the purity and yield of the antibody.
It achieves high yield and high purity of monoclonal antibodies, reduces solid tumor rate, simplifies operating procedures, reduces production costs, and is suitable for large-scale production and clinical applications.
Smart Images

Figure BDA0004967524510000091 
Figure BDA0004967524510000092 
Figure BDA0004967524510000101
Abstract
Description
Technical Field
[0001] The present invention relates to a monoclonal antibody preparation technology, and in particular to a method for preparing a monoclonal antibody in vivo and its application. Background Art
[0002] At present, monoclonal antibodies are mainly used in the prevention, diagnosis and treatment of diseases, purification of biological substances and research on protein structure and function. The market for therapeutic monoclonal antibodies has a growing trend in the development of new drugs year by year, and monoclonal antibody technology is a rising star in the field of biotechnology. With the continuous deepening of research on monoclonal antibody drugs and the continuous introduction of new drugs, monoclonal antibody drugs have been at a high growth rate. Monoclonal antibodies are not only widely used in in vitro diagnostic reagents, but can also be directly used in the diagnosis, prevention, treatment and immune mechanism research of human diseases, opening up broad prospects for immune diagnosis and immunotherapy of human malignant tumors.
[0003] my country's monoclonal antibody drugs have developed rapidly from scratch and have played an increasingly important role in my country's pharmaceutical market. However, monoclonal antibodies are still high-end products in my country's market and mainly rely on imports. There are two main systems for preparing monoclonal antibodies widely used in domestic and foreign laboratories: one is in vitro culture method; the other is animal in vivo production method.
[0004] Among them, the production of monoclonal antibodies in animals is widely used. Since most hybridomas for animals are obtained by fusion of myeloma cells of BALB / c mice with spleen cells of the same strain, only BALB / c mice can be selected for the in vivo preparation of monoclonal antibodies due to affinity, and other strains cannot be prepared; strain limitation is a bottleneck that is difficult to overcome for this technology. By inoculating hybridoma cells into the peritoneal cavity of mice, hybridomas grow in the peritoneal cavity of mice, and ascites is produced, a large amount of ascites monoclonal antibodies with high antibody concentrations are obtained. Although this method is simple and economical to operate, the ascites rate of traditional BALB / c mice is low, and other strains of mice cannot produce ascites in vivo. In the actual operation process, the experimental cost is high and the process is complicated, which is not conducive to large-scale production and preparation, resulting in high clinical trials and pharmaceutical costs.
[0005] With the continuous deepening of monoclonal antibody drug research and the continuous introduction of new drugs, the global monoclonal antibody drug has been at a high growth rate, and the widespread application of in vitro diagnostic reagents has promoted the exploration of low-cost, high-purity new process methods for monoclonal antibody purification. Conventional technologies include ammonium sulfate octanoate method and various chromatography techniques for purification. However, in the preparation process of the conventional ammonium sulfate octanoate method, it is not only limited by the batch production of low-temperature high-speed centrifuges, but also has a long dialysis cycle and is prone to low yield and substandard purity. In the process of using various chromatography techniques, various active materials such as fillers are involved, resulting in high costs and complex processes, which has brought great economic difficulties to the expansion of production and industrial production to focus on human clinical trials and medicine in general. Summary of the invention
[0006] In view of this, the technical problem to be solved by the present invention is to provide a method for preparing monoclonal antibodies in vivo and its application.
[0007] The present invention provides a method for preparing a monoclonal antibody, comprising:
[0008] The first-generation mice were obtained by hybridization with BALB / c mice as the father and PT mice as the mother. The abdominal cavity of the mice was pre-treated and then injected with the domesticated hybridoma cell suspension. The mouse ascites was then collected and purified to obtain monoclonal antibodies.
[0009] Furthermore,
[0010] The male BALB / c mice are 20 to 22 weeks old;
[0011] The maternal PT mice were 20 to 22 weeks old.
[0012] In the present invention, various parameters in the preparation method of monoclonal antibodies were tried many times, including the selection of mouse hybrid parents:
[0013] In some embodiments of the present invention, the male parent is a 20-22 week old BALB / c mouse, and the female parent is a 20-22 week old PT mouse;
[0014] In some embodiments of the present invention, the male parent is a 20-22 week old BALB / c mouse, and the female parent is a 6-10 week old PT mouse;
[0015] In other embodiments of the present invention, the father is a BALB / c mouse of 6 to 10 weeks of age, and the mother is a BALB / c mouse of 6 to 10 weeks of age;
[0016] In other embodiments of the present invention, the father is a 20-22 week old PT mouse, and the mother is a 20-22 week old BALB / c mouse;
[0017] The experimental results showed that only the first-generation mice obtained by hybridizing 20-22 week-old BALB / c mice as the father and 20-22 week-old PT mice as the mother had a much higher amount of ascites after treatment than other forms of hybrid mice, and the concentration of monoclonal antibodies in the ascites increased, and the rate of solid tumors in mice decreased; changing the father line of the hybrid mouse model made it impossible to prepare ascites of the relevant monoclonal antibodies.
[0018] In the present invention, conventional experiments mostly use 6-10 week old PT mice, which are relatively small in size. The larger PT mice used in this experiment are 20-22 week old PT mice. The experimental results show that the amount of ascites and the content of ascites antibodies are high after treatment when the first generation of mice are hybridized with larger PT mice as the mother.
[0019] In the present invention, the pretreatment includes: intraperitoneal injection of paraffin and intraperitone injection of pristane.
[0020] Furthermore,
[0021] The mice were 15 to 16 weeks old when the paraffin was intraperitoneally injected, and the injection volume was 0.8 ml / mouse.
[0022] The time of intraperitoneal injection of pristane is 4 to 5 weeks after intraperitoneal injection of paraffin, and the injection volume is 0.8 ml / mouse.
[0023] In the preparation method described in the present invention, various attempts were made to pretreat the mouse peritoneal cavity. In some embodiments of the present invention, only paraffin was used to treat the mouse peritoneal cavity; in other embodiments of the present invention, paraffin and pristane were used to treat the mouse peritoneal cavity together; the experimental results showed that after the mouse peritoneal cavity was desensitized by treating the mouse peritoneal cavity with paraffin and pristane together, the mouse ascites production increased, the antibody concentration in the mouse ascites increased, and the mouse solid tumor rate decreased.
[0024] In the present invention, the density of hybridoma cells in the hybridoma cell suspension is (6-8)×10 6 The injection dose is 0.5 ml / mouse.
[0025] Furthermore, the mice are 20 to 22 weeks old when the domesticated hybridoma cells are injected; in the present invention, the optimal age of the mice injected with hybridoma cells is 20 to 22 weeks old. Older mice have stronger immunity and have a significant advantage in ascites production.
[0026] Furthermore, the method of taming the hybridoma cell suspension for injection taming is shake flask suspension culture, and the parameters of the shake flask suspension culture include: 25-100 amplitude, 50-130r / min, 37°C, 5% CO 2 .
[0027] In the preparation method of the present invention, the hybridoma cell concentration is different, and the quality of the mouse ascites after injection treatment is different:
[0028] In some embodiments of the present invention, the hybridoma cell concentration is 1×10 6 / ml, the injection dose is 0.5ml / piece;
[0029] In other embodiments of the present invention, the hybridoma cell concentration is 8×10 6 / ml, the injection dose is 0.5ml / piece;
[0030] In some other embodiments of the present invention, the hybridoma cell concentration is 6×10 6 / ml, the injection dose is 0.5ml / piece;
[0031] The experimental results showed that the concentration of hybridoma cells was (6-8)×10 6 / ml After injection into mice, the ascites production was large, the ascites antibody content was high, and the solid tumor rate of mice was low.
[0032] In the preparation method described in the present invention, the hybridoma cell acclimation method is different and the acclimation process parameter settings are different, and the quality of mouse ascites after injection treatment is different:
[0033] In some embodiments of the present invention, the hybridoma cells are cultured in a semi-adherent and semi-suspension state;
[0034] In other embodiments of the present invention, the hybridoma cells are cultured in a shake flask suspension culture, and the parameters may be 25 amplitude 50r / min;
[0035] In other embodiments of the present invention, the hybridoma cells are cultured in a shake flask suspension culture, and the parameters may be 25 amplitude 100 r / min;
[0036] In some other embodiments of the present invention, the hybridoma cells are cultured in a shake flask suspension culture, and the parameters may be 25 amplitude 130r / min;
[0037] In other embodiments of the present invention, the hybridoma cells are cultured in a shake flask suspension culture, and the parameters may be 50 amplitude 50r / min;
[0038] In other embodiments of the present invention, the hybridoma cells are cultured in a shake flask suspension culture, and the parameters may be 50 amplitude 100 r / min;
[0039] In other embodiments of the present invention, the hybridoma cells are cultured in a shake flask suspension culture, and the parameters may be 50 amplitude 130 r / min;
[0040] The experimental results show that the effect of suspension culture using shake flasks is better than that of semi-adherent semi-suspension culture, and the hybridoma cells obtained by suspension culture in shake flasks at an amplitude of 50 and a speed of 100r / min have a higher viability, a higher density, and a lower agglomeration rate, which better meets the experimental needs.
[0041] In the preparation method of the present invention, the purification steps sequentially include: ammonium sulfate salting out, filtration, concentration and replacement of buffer solution.
[0042] The filtration uses a filter membrane, and the filter diameter of the filter membrane is 0.45 μm and / or 0.22 μm.
[0043] The buffer solution is an aqueous solution containing 55 vol% glycerol and 5 vol% trehalose.
[0044] The hybridoma cell described in the present invention is a hybridoma cell that secretes the target antibody. In some embodiments of the present invention, the hybridoma cell may be a hybridoma cell that secretes Epstein-Barr virus antibodies, a hybridoma cell that secretes myelin basic protein antibodies, or a hybridoma cell that secretes alpha-fetoprotein antibodies; in other embodiments of the present invention, the hybridoma cell may be a hybridoma cell that secretes canine hepatitis C virus antibodies, a hybridoma cell that secretes monkeypox antibodies, or a hybridoma cell that secretes hepatitis C virus antibodies; the present invention uses a variety of hybridoma cells that secrete the target antibody, which are not described one by one.
[0045] In the present invention, the hybridoma cells containing antibodies are injected into mice, so that the mice produce ascites of the corresponding antibodies, which are purified to prepare monoclonal antibodies. Experimental results show that the preparation method of the present invention is effective for the production of different antibodies, the method has a high yield of monoclonal antibodies, and the method has universal applicability.
[0046] In the preparation method described in the present invention, the selection of the age of the parent mice and the type of the parent mice will affect the yield and quality of the mouse ascites. The yield and quality of the mouse ascites are optimal after hybridization treatment in which the male parent is a 20-22-week-old BALB / c mouse and the female parent is a 20-22-week-old PT mouse. Furthermore, the mouse peritoneal pretreatment, injection of hybridoma cells, hybridoma cell acclimation method and cell density will all affect the quality and yield of the mouse ascites. After the mice are treated with the preparation method described in the present invention, the purity of the monoclonal antibody purified is above 98%, and the purification yield is 21.9 mg / ml to 28.0 mg / ml.
[0047] The present invention provides the use of PT mice in preparing monoclonal antibodies.
[0048] The invention provides a monoclonal antibody prepared by the preparation method.
[0049] Further, the present invention provides products of excipients and monoclonal antibodies. The excipients include but are not limited to cleaning antibodies, enzymes, fluorescent dyes, biotin, colloidal gold, etc.; the cleaning antibodies include CTNI, EB, MBP, etc. The enzymes include but are not limited to horseradish peroxidase (HRP) and / or alkaline phosphatase (AP); the fluorescent dyes include but are not limited to fluorescein isothiocyanate (FITC), rhodamine, cyanine fluorescent dyes, acridine, phenanthridine, chalcone, coumarins, condensed aromatic hydrocarbons, thiazine / oxazine, dansylamide, porphyrins, etc.
[0050] The present invention cultured the first generation mouse model formed by hybridization of BALB / c mice and PT mice for 15 to 16 weeks, and then pretreated its abdominal cavity twice with paraffin and pristane, and then injected a specific concentration of domesticated and propagated hybridoma cells, and then purified the mouse ascites to obtain monoclonal antibodies. The results showed that the ascites yield of a single hybrid mouse model obtained by the method of the present invention reached 42 to 50 ml; the monoclonal antibody yield could reach 28 mg / ml, and the purity was above 98%. The method of the present invention has a simple process, convenient operation, high safety, and the obtained monoclonal antibody has an excellent blocking effect when applied to the detection kit, and can be further used in the medical in vitro diagnosis industry. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 It shows that hybridoma cell lines were taken out and revived from the seed bank;
[0052] Figure 2 Shows the status of hybridoma cells before injection;
[0053] Figure 3 The figure shows the comparison of ascites growth rate between the method of the present invention and the control method;
[0054] Figure 4 The solid tumor rate comparison of the method of the present invention and the control method is shown. DETAILED DESCRIPTION
[0055] The present invention provides methods and applications for preparing monoclonal antibodies in vivo, and those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0056] The PT mice used in the present invention are older than conventional experimental mice, and are mainly PT mice a few weeks after adulthood. Literature and conventional experiments mostly use 6-10 weeks old mice. After the experiment of the present invention, it was found that the best age of mice inoculated with hybridoma cells is 20-22 weeks, at which time the mice are larger in size and have stronger immunity.
[0057] In the present invention, BALB / c mice and PT common mice are bred and mated in a ratio of 2:1 (3 mice / cage), and the offspring mice after mating need to be cultured in separate cages for 3 to 4 weeks to avoid mixing different generations.
[0058] In the present invention, the hybridoma cell line is taken out from the seed bank for recovery, subcultured and expanded to a shake bottle for acclimation and suspension growth and reproduction, then cultured to the logarithmic growth phase, and then the specific steps of cell pretreatment and counting include:
[0059] (1) Prepare the required amount of DMEM basal medium and complete medium for the experiment, place them in a 37.5℃ electric constant temperature water bath to warm up for 30 minutes; after warming up, wipe the surface of the reagent bottle with 75% alcohol, move to the clean bench, add 20ml of DMEM basal medium to a 50ml sterile centrifuge tube and set aside. Take out the cells from the liquid nitrogen tank, quickly place them in a 37.5℃ water bath to thaw (shake the cryopreservation tube gently, or use an internal circulation constant temperature water bath), wipe the surface of the cryopreservation tube with a dry cotton ball, and move to the clean bench. After resuspending the cells in the cryopreservation tube with a 1ml pipette, slowly add 1 to 2cm below the liquid surface to a 50ml centrifuge tube containing 20ml of DMEM basal medium, blow gently to mix, mark the tube wall with detailed cell information, and centrifuge at 1000rpm for 3 minutes. After centrifugation, remove the centrifuge tube, move it to the clean bench, discard the supernatant, and repeat washing 5 times to effectively remove toxic substances such as dimethyl sulfoxide in the hybridoma cell freezing solution to ensure the survival rate of the hybridoma cells after thawing; aspirate 1 ml of culture medium from the Φ10 cm cell culture dish containing the feeder cell working solution to resuspend the cells (the feeder cells use mouse peritoneal macrophages, and the culture medium is a complete culture medium, i.e., DMEM culture medium containing 30% serum). After resuspension, add it to the Φ10 cm cell culture dish containing the feeder cell working solution in a "Z" shape, blow gently to mix, and place in a 37°C 5% CO2 incubator for culture. The next day, observe under the 10 / 20x objective lens of an inverted microscope. The hybridoma cells are evenly distributed on the bottom of the Φ10 cm culture dish, and the cells are in good condition and free of contamination. Figure 1 .
[0060] (2) Cell passaging: Take out the cell culture dish from the incubator and observe the cell morphology under an inverted microscope at 10 / 20x magnification. When the cells grow to be round, plump, and translucent and cover 3 / 5 of the bottom of the Φ10 cm culture dish, they can be passaged.
[0061] (3) Move the cell culture dish to the clean bench, resuspend and add to a 50 ml sterile centrifuge tube, and centrifuge at 1000 rpm for 3 min. Discard the supernatant and resuspend the cells in 5 ml complete medium. According to the principle of transferring one dish to one bottle, slowly add to a 250 ml cell culture shake flask containing feeder cell working solution and place at 37°C 5% CO 2 The shaker incubator was used for culture. The shaker parameters were adjustable, and the optimal values were 50 amplitude and 100 r / min. The cells were subcultured to 500 ml cell culture shake flasks every other day; the cells were subcultured to 1000 ml cell culture shake flasks every other day; the next day, 20 μl of the cell suspension was aseptically taken and observed under a cell counter, and counted without contamination.
[0062] (4) Cell injection: Take out the cell culture shaker from the incubator, take a small amount of cell suspension and observe the cell morphology under an inverted microscope or cell counter. If the cells grow to be round, plump, and translucent, and the total number of cells counted back meets the injection requirements, the injection can be performed. Figure 2 ; Before injection, select hybrid mouse models that meet the requirements of a round and full abdomen, no scars on the body, bright eyes, and strong limbs.
[0063] (5) Move the cell culture shake flask to the clean bench, resuspend and dispense equal amounts into 50ml sterile centrifuge tubes, centrifuge at 1000rpm for 5min, and discard the supernatant. First wash: add 3ml of normal saline to resuspend the cells; after resuspension, combine the tubes according to the principle of <10 centrifuge tubes (culture dishes) at a time, add normal saline to 45ml, mix thoroughly, centrifuge at 1000rpm for 5min, and discard the supernatant. Second wash: first add 5ml of normal saline to resuspend the cells, then add to 45ml, mix upside down, centrifuge at 1000rpm for 5min, and discard the supernatant. Cell counting: first add 5ml of normal saline to resuspend the cells, then add to 10ml, blow gently to mix, resuspend with 0.4% trypan blue 1:1, and count with a cell counter (based on the number of cells injected into a single hybrid mouse model of 3-4×10 6 ), third wash: add 45 ml of saline, gently pipette to mix, centrifuge at 1000 rpm for 5 min, and discard the supernatant. Add 5 ml of saline to resuspend the cells, refer to the cell count data, and adjust the hybridoma cell density to 6-8×10 with saline. 6 Pieces / ml.
[0064] In the present invention, the mouse model is observed, and the collection time and method of continuously collecting samples at intervals until death after ascites is formed are specifically as follows:
[0065] Observe the mouse model, and collect ascites when the color of the abdomen becomes darker and obviously swollen. Fix the mouse with one hand to expose its abdomen completely, and quickly insert the needle with a 1.2mm needle from the lower right of the center line of the mouse abdomen to 1 / 3 of the thigh (use the safe ascites continuous collection needle with patent number CN212699220U), gently rotate the needle, and press the mouse abdomen with the fingertips slightly to make the ascites flow out naturally into a 50ml centrifuge tube, and mark the product name. After the collection is completed, centrifuge at 4000rpm for 3min, remove the cell components and other insolubles (use the filter spoon with patent number CN206138812U suitable for the treatment of floating objects after ascites centrifugation), collect the supernatant, and temporarily store the supernatant in a -20℃ freezer for use. The collection can be continued at intervals of 10 to 20 days.
[0066] The project names described in the following tables refer to the use of hybridoma cell lines that secrete the target antibody to inject mice. The names of the antibodies contained in the hybridoma cells are different from the names of the strains, so the project names are also different.
[0067] Explanation and function of cleaning antibodies: Heterophilic antibodies in human serum have been shown to cause false positive or false negative interference in immunoassays. Heterophilic samples refer to serum or plasma samples containing specific antibodies that bind to animal antibodies used in immunochemical assays. Heterophilic antibody interference leads to false positives or false negatives. The false positive rate caused by heterophilic antibody interference is as high as 22%. Adding cleaning antibodies to the conjugate of the immunoassay system can eliminate the interference of heterophilic antibodies.
[0068] The test materials used in the present invention are all common commercial products and can be purchased in the market.
[0069] The present invention will be further described below in conjunction with embodiments:
[0070] Example 1 Effect of Mouse Selection on Mouse Monoclonal Antibody Ascites Production
[0071] 1. Treatment of Experimental Group 1
[0072] In the first step, 22-week-old BALB / c mice were mated with 21-week-old PT mice to form a first-generation mouse model;
[0073] In the second step, this generation of mouse model is called a hybrid mouse model. After the hybrid mouse model is cultured for 12 weeks, it is pretreated for 5 weeks for use. The specific treatment method is to inject liquid paraffin after the hybrid mouse model is cultured for 12 weeks, and inject 0.5 ml of liquid paraffin into the abdominal cavity for each hybrid mouse.
[0074] The third step is to take out the hybridoma cell line secreting monoclonal antibodies from the seed bank, revive it, and subculture it on several plates until it reaches the logarithmic growth phase, and then perform cell pretreatment and counting;
[0075] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 1×10 6 / ml, and the hybridoma cells were injected into the peritoneal cavity of 17-week-old pretreated hybrid mouse model at 0.5ml / mouse using a sterile continuous syringe.
[0076] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0077] 2. Treatment of Control Group 1
[0078] In the first step, 8-week-old BALB / c mice were mated with 8-week-old BALB / c mice to form a first-generation mouse model;
[0079] In the second step, after culturing this first generation mouse model to 12 weeks, pre-treat it for 5 weeks for use. The specific treatment method is to inject liquid paraffin after culturing the hybrid mouse model to 12 weeks, and inject 0.5 ml of liquid paraffin into the abdominal cavity for each hybrid mouse.
[0080] The third step is to take out the hybridoma cell line secreting monoclonal antibodies from the seed bank, revive it, and subculture it on several plates until it reaches the logarithmic growth phase, and then perform cell pretreatment and counting;
[0081] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 1×10 6 / ml, and the hybridoma cells were injected into the peritoneal cavity of 17-week-old pretreated hybrid mouse model at 0.5ml / mouse using a sterile continuous syringe.
[0082] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0083] 3. Results
[0084] The ascites volume and 1ABS concentration of mice after hybridization of different mice are shown in Table 1 , and the ascites growth rate and solid tumor rate of mice are shown in Table 2 .
[0085] Table 1. Effect of mouse selection on ascites production of mouse monoclonal antibodies
[0086]
[0087] Table 2. Effect of mouse selection on ascites growth rate and solid tumor rate of hybrid mouse monoclonal antibodies
[0088]
[0089] The antibodies secreted by the hybridoma cell lines of the project are: S monoclonal antibody is SAA (serum amyloid protein); M monoclonal antibody is Mpox (monkeypox antibody); H monoclonal antibody is HCV-NS3 (hepatitis C virus antibody).
[0090] The experimental results showed that the amount of ascites in a single mouse obtained by mating 22-week-old BALB / c mice with 21-week-old PT mice was much higher than that of conventional BALB / c mice, and the protein concentration was also advantageous. However, the growth rate of ascites in mice was low, and the phenomenon of solid tumors in the abdominal cavity of the mouse model was serious in the later stage of collection, which needs to be optimized.
[0091] Example 2 Effects of different mouse peritoneal treatments on the production of monoclonal antibody ascites in hybrid mice
[0092] 1. Treatment of Experimental Group 2
[0093] In the first step, 20-week-old BALB / c mice were mated with 20-week-old PT mice to form a first-generation mouse model;
[0094] The second step is to call this generation of mouse model a hybrid mouse model. After the hybrid mouse model is cultured for 15 weeks, it is pretreated for 5 weeks for standby use. The specific treatment method is to inject liquid paraffin into the hybrid mouse model after it is cultured for 15 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse. Then, after continuing to culture for 5 weeks, it is pretreated with pristane one week before preparing to inject hybridoma cells, and inject 0.8 ml of pristane into the abdominal cavity for each hybrid mouse, and then continue to culture for standby use.
[0095] The third step is to take out the hybridoma cell line secreting monoclonal antibodies from the seed bank, revive it, and subculture it on several plates until it reaches the logarithmic growth phase, and then perform cell pretreatment and counting;
[0096] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 1×10 6 The hybridoma cells were injected into the peritoneal cavity of 21-week-old pretreated hybrid mouse models at a rate of 0.5 ml / mouse using a sterile continuous syringe.
[0097] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0098] 2. Treatment of Control Group 2
[0099] In the first step, 20-week-old BALB / c mice were mated with 20-week-old PT mice to form a first-generation mouse model;
[0100] In the second step, after culturing this first generation mouse model to 12 weeks, pre-treat it for 5 weeks for use. The specific treatment method is to inject liquid paraffin after culturing the hybrid mouse model to 12 weeks, and inject 0.5 ml of liquid paraffin into the abdominal cavity for each hybrid mouse.
[0101] The third step is to take out the hybridoma cell line secreting monoclonal antibodies from the seed bank, revive it, and subculture it on several plates until it reaches the logarithmic growth phase, and then perform cell pretreatment and counting;
[0102] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 1×10 6 / ml, and the hybridoma cells were injected into the peritoneal cavity of 17-week-old pretreated hybrid mouse model at 0.5ml / mouse using a sterile continuous syringe.
[0103] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0104] 3. Results:
[0105] The results are shown in Tables 3 and 4.
[0106] Table 3. Effects of different mouse peritoneal treatments on the production of monoclonal antibody ascites in hybrid mice
[0107]
[0108]
[0109] Table 4. Effects of different mouse peritoneal treatments on the ascites growth rate and solid tumor rate of hybrid mouse monoclonal antibodies
[0110]
[0111] The hybridoma cell lines of the project secrete antibodies: S01 monoclonal antibody is S100 antibody; M01 monoclonal antibody is m3 (anti-muscarinic 3 receptor antibody); H01 monoclonal antibody is HCV-coreAg (canine hepatitis C virus antibody).
[0112] The results showed that the hybrid mouse model pretreatment process of the present invention was used to perform two intervals of immunization, which could increase the growth rate of mouse ascites and reduce the growth rate of abdominal solid tumors, and the overall ascites collection volume was significantly improved.
[0113] Example 3 Effect of hybridoma cell seeding density on the production of monoclonal antibody ascites in hybrid mice
[0114] 1. Treatment of Experimental Group 3
[0115] In the first step, 22-week-old BALB / c mice were mated with 22-week-old PT mice to form a first-generation mouse model;
[0116] The second step is to call this generation of mouse model a hybrid mouse model. After the hybrid mouse model is cultured for 15 weeks, it is pretreated for 5 weeks for standby use. The specific treatment method is to inject liquid paraffin into the hybrid mouse model after it is cultured for 15 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse. Then, after continuing to culture for 5 weeks, it is pretreated with pristane one week before preparing to inject hybridoma cells, and inject 0.8 ml of pristane into the abdominal cavity for each hybrid mouse, and then continue to culture for standby use.
[0117] In the third step, the hybridoma cell line secreting monoclonal antibodies was taken out from the seed bank for recovery and subculture, and then acclimated and suspended in a shake flask for growth and reproduction (50 amplitude, 100 r / min, 37°C, 5% CO). 2 ), then cultured to the logarithmic growth phase, and then pretreated and counted the cells;
[0118] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 6×10 6 The hybridoma cells were injected into the peritoneal cavity of 21-week-old pretreated hybrid mouse models at a rate of 0.5 ml / mouse using a sterile continuous syringe.
[0119] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0120] 2. Control group 3 treatment:
[0121] In the first step, 22-week-old BALB / c mice were mated with 22-week-old PT mice to form a first-generation mouse model;
[0122] The second step is to call this generation of mouse model a hybrid mouse model. After the hybrid mouse model is cultured for 15 weeks, it is pretreated for 5 weeks for standby use. The specific treatment method is to inject liquid paraffin into the hybrid mouse model after it is cultured for 15 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse. Then, after continuing to culture for 5 weeks, it is pretreated with pristane one week before preparing to inject hybridoma cells, and inject 0.8 ml of pristane into the abdominal cavity for each hybrid mouse, and then continue to culture for standby use.
[0123] The third step is to take out the hybridoma cell line secreting monoclonal antibodies from the seed bank, revive it, and subculture it on several plates until it reaches the logarithmic growth phase, and then perform cell pretreatment and counting;
[0124] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 1×106 The hybridoma cells were injected intraperitoneally into the pretreated hybrid mouse model at 17 weeks of age using a sterile continuous syringe.
[0125] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0126] 3. Results
[0127] The specific results are shown in Table 5 and Table 6:
[0128] Table 5. Effects of hybridoma cell inoculation density and acclimation method on the production of monoclonal antibody ascites in hybrid mice
[0129]
[0130] Table 6. Effects of hybridoma cell inoculation density and acclimation method on the ascites growth rate and solid tumor rate of hybrid mouse monoclonal antibody
[0131]
[0132] The antibodies secreted by the hybridoma cell lines of the project are: S0X monoclonal antibody is EPX (eosinophil peroxidase antibody); M0B monoclonal antibody is MBP (myelin basic protein antibody); H0Y monoclonal antibody is AFP (alpha-fetoprotein antibody).
[0133] The results showed that the hybridoma cell domestication by the present invention and the adjustment of the inoculation density can greatly improve the growth rate of mouse ascites and reduce the growth rate of abdominal solid tumors, and the overall ascites collection volume and concentration are significantly improved.
[0134] Example 4 Effects of hybridoma cell culture and mouse age on ascites production Further study 1. Effect of mouse parental gender on ascites production
[0135] In the first step, the parents shown in Table 7 are used for group hybridization to form a first-generation mouse model;
[0136] The second step is to call this generation of mouse model a hybrid mouse model. After the hybrid mouse model is cultured for 15 weeks, it is pretreated for 5 weeks for standby use. The specific treatment method is to inject liquid paraffin into the hybrid mouse model after it is cultured for 15 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse. Then, after continuing to culture for 5 weeks, it is pretreated with pristane one week before preparing to inject hybridoma cells, and inject 0.8 ml of pristane into the abdominal cavity for each hybrid mouse, and then continue to culture for standby use.
[0137] In the third step, the hybridoma cell line secreting monoclonal antibodies was taken out from the seed bank for recovery and subculture, and then acclimated and suspended in a shake flask for growth and reproduction (50 amplitude, 100 r / min, 37°C, 5% CO). 2 ), then cultured to the logarithmic growth phase, and then pretreated and counted the cells;
[0138] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 6×10 6 The hybridoma cells were injected into the peritoneal cavity of 21-week-old pretreated hybrid mouse models at a rate of 0.5 ml / mouse using a sterile continuous syringe.
[0139] Step 5. Observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death. The ascites collection and antibody concentration of mice are shown in Table 7.
[0140] Table 7. Effects of mouse parentage and age on the growth of monoclonal antibody ascites in hybrid mice
[0141]
[0142] Project A011 is EB (Epstein-Barr virus antibody).
[0143] 2. Effects of Different Treatments of Hybridoma Cell Culture on Ascites Production in Mice
[0144] 1. Experimental group
[0145] In the first step, 22-week-old BALB / c mice were mated with 21-week-old PT mice to form a first-generation mouse model;
[0146] The second step is to call this generation of mouse model a hybrid mouse model. After the hybrid mouse model is cultured for 15 weeks, it is pretreated for 5 weeks for standby use. The specific treatment method is to inject liquid paraffin into the hybrid mouse model after it is cultured for 15 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse. Then, after continuing to culture for 5 weeks, it is pretreated with pristane one week before preparing to inject hybridoma cells, and inject 0.8 ml of pristane into the abdominal cavity for each hybrid mouse, and then continue to culture for standby use.
[0147] In the third step, the hybridoma cell line secreting monoclonal antibodies was taken out from the seed bank for recovery and subculture, and then acclimated and suspended in a shake flask for growth and reproduction (50 amplitude, 100 r / min, 37°C, 5% CO). 2 ), then cultured to the logarithmic growth phase, and then pretreated and counted the cells;
[0148] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 6×10 6The hybridoma cells were injected into the peritoneal cavity of 21-week-old pretreated hybrid mouse models at a rate of 0.5 ml / mouse using a sterile continuous syringe.
[0149] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0150] 2. Control group
[0151] In the first step, 22-week-old BALB / c mice were mated with 21-week-old PT mice to form a first-generation mouse model;
[0152] The second step is to call this generation of mouse model a hybrid mouse model. After the hybrid mouse model is cultured for 15 weeks, it is pretreated for 5 weeks for standby use. The specific treatment method is to inject liquid paraffin into the hybrid mouse model after it is cultured for 15 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse. Then, after continuing to culture for 5 weeks, it is pretreated with pristane one week before preparing to inject hybridoma cells, and inject 0.8 ml of pristane into the abdominal cavity for each hybrid mouse, and then continue to culture for standby use.
[0153] The third step is to take out the hybridoma cell line secreting monoclonal antibodies from the seed bank, revive it, and subculture it on several plates until it reaches the logarithmic growth phase, and then perform cell pretreatment and counting;
[0154] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 6×10 6 The hybridoma cells were injected intraperitoneally into the pretreated hybrid mouse model at 21 weeks of age using a sterile continuous syringe.
[0155] The fifth step is to observe the mouse model after injection. After ascites develops, samples can be collected at intervals until death.
[0156] The results are shown in Table 8
[0157] Table 8. Effect of hybridoma cell culture method on the growth of hybrid mouse monoclonal antibody ascites
[0158]
[0159] The antibodies secreted by the hybridoma cell lines of the project are: AY001 monoclonal antibody is ProGRP (gastrin-releasing peptide precursor antibody); AY021 monoclonal antibody is colo 205 (colon cancer cell antibody); AY046 monoclonal antibody is CTNT (cardiac troponin T antibody).
[0160] Example 5 Preparation and purification of monoclonal antibodies of the present invention
[0161] 1. Experimental Group 4 Treatment
[0162] After summarizing the above examples and trying them together, the method for establishing a mouse model for preparing monoclonal antibodies of the present invention is carried out according to the following steps:
[0163] In the first step, 22-week-old BALB / c mice were mated with 20-week-old PT mice to form a first-generation mouse model, which is called a hybrid mouse model;
[0164] The second step is to call this generation of mouse model a hybrid mouse model. After the hybrid mouse model is cultured for 15 to 16 weeks, it is pretreated for 5 to 6 weeks for standby use. The specific treatment method is to inject liquid paraffin into the hybrid mouse model after it is cultured for 15 to 16 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse. Then, after continuing to culture for 4 to 5 weeks, 1 to 2 weeks before preparing to inject hybridoma cells, pretreat with pristane, and inject 0.8 ml of pristane into the abdominal cavity for each hybrid mouse, and then continue to culture for standby use.
[0165] In the third step, the hybridoma cell line secreting monoclonal antibodies was taken out from the seed bank for recovery and subculture to a shake flask for acclimation and suspension growth, and then cultured to the logarithmic growth phase, and then the cells were pretreated and counted. The speed parameters of the acclimation and suspension growth in the shake flask were adjusted, as shown in Table 9, and the cells were detected using a COUNT STAR automatic cell counter (model: IC1000).
[0166] Table 9. Effects of different hybridoma cell culture parameters on hybridoma cell growth
[0167]
[0168]
[0169] After experimental comparative analysis, the hybridoma cells obtained by selecting a shaker with an amplitude of 50 and a speed of 100 r / min during the shake flask acclimation process had a higher viability, a larger density, and a lower agglomeration rate, which better met the experimental requirements. Therefore, the hybridoma cells obtained by selecting a shaker with an amplitude of 50 and a speed of 100 r / min were selected for subsequent experiments.
[0170] In the fourth step, the hybridoma cell line treated in the third step is injected into the peritoneal cavity of the pretreated hybrid mouse model of 20 to 22 weeks old using a sterile continuous syringe at a volume of 0.5 ml / mouse.
[0171] The fifth step is to observe the mouse model from the 10th day after the hybridoma cell injection, and continue to collect samples at intervals until death after ascites develops.
[0172] 2. Control Group 4 Treatment
[0173] In the first step, 22-week-old BALB / c mice were mated with 20-week-old BALB / c mice to form a first-generation mouse model;
[0174] In the second step, after culturing this first generation mouse model to 15 weeks, pre-treat it for 6 weeks for use. The specific treatment method is to inject liquid paraffin after culturing the hybrid mouse model to 15 weeks, and inject 0.8 ml of liquid paraffin into the abdominal cavity for each hybrid mouse.
[0175] The third step is to take out the hybridoma cell line secreting monoclonal antibodies from the seed bank, revive it, and subculture it on several plates until it reaches the logarithmic growth phase, and then perform cell pretreatment and counting;
[0176] Step 4: Referring to the principle of cell counting, adjust the density of hybridoma cells to 1×10 6 The hybridoma cells were injected intraperitoneally into the pretreated hybrid mouse model at 21 weeks of age using a sterile continuous syringe.
[0177] The fifth step is to observe the mouse model. After ascites develops, samples can be collected at intervals until death.
[0178] 3. Results of Ascites Production
[0179] The specific example results are shown in Table 10. The ascites growth rate and solid tumor rate are Figure 3 and Figure 4 As shown:
[0180] Table 10. Comparison of ascites growth of hybrid mouse monoclonal antibodies between the control group and the experimental group
[0181]
[0182]
[0183] The antibodies secreted by the hybridoma cell lines of the project are: K monoclonal antibody is TSHR (thyroid stimulating hormone receptor antibody); H monoclonal antibody is NSE (neuron-specific enolase antibody); C monoclonal antibody is COX (human cyclooxygenase antibody); P monoclonal antibody is INS (insulin antibody); E monoclonal antibody is Arah (peanut allergen Ara antibody).
[0184] The results showed that the ascites yield of a single hybrid mouse model obtained in the experimental group reached 42 to 50 ml. The ascites obtained was fully mixed and tested. The A280 test showed that the 1ABS concentration was 63 to 70 mg / ml, which was much higher than the ascites obtained by the conventional method (the control group of Example 5). Its higher protein content was conducive to the later purification of samples and the harvest of a large amount of target protein. The ascites growth rate of the experimental group of this example was higher and the solid tumor rate was lower, with obvious overall advantages.
[0185] 4. Ascites Purification
[0186] (I) Experimental Group 5 Treatment:
[0187] First, the ascites is thoroughly mixed, filtered and other pre-treatments are performed, and then the filtered saturated ammonium sulfate solution is used for multiple salting out according to gradient concentration to remove the impurity protein in the sample; deep filtration is used to separate the supernatant, and then the hollow fiber concentration method is used to efficiently concentrate the target protein solution and replace the buffer at the same time. The replaced buffer contains 55 vol% glycerol and 5% vol% trehalose.
[0188] (ii) Control group 5 treatment:
[0189] The purification steps of the ammonium sulfate caprylate process in the control group include caprylate precipitation to remove impurities, high-speed centrifugation to collect the supernatant, then adding ammonium sulfate solid and stirring thoroughly, high-speed centrifugation to collect the precipitate, redissolving the precipitate, dialysis overnight, and changing the dialysate several times in the middle until the desalination is completely qualified. The principle is: the caprylate-ammonium sulfate method is carried out in two steps. The first step is to precipitate impurities with caprylate. Caprylate is a short-chain fatty acid that can precipitate albumin or other non-Ig proteins in serum or ascites under acidic conditions; the second step is to precipitate Ig by ammonium sulfate salting out. Ig with high electrophoretic purity can be obtained by SDS-PAGE electrophoresis.
[0190] (III) Results
[0191] The specific experimental results are shown in Table 9. The ascites purification yield in experimental group 5 can reach 28 mg / ml, and the final monoclonal antibody purity is above 98%. Some items can be close to 100% after SDS-PAGE and HPLC analysis. This purification process not only avoids the changes in protein structure and capacity limitations caused by high-speed centrifugation, reduces the cost of purification process, and has a short purification cycle; it effectively avoids the reduction of protein activity and blocking ability caused by repeated freezing and thawing during later use.
[0192] In addition, the recovery rate of the target protein in the purification process of experimental group 5 was higher, and the purity was also better than that of the octanoic acid ammonium sulfate process in the control group. In addition, the octanoic acid-ammonium sulfate process takes about 2 days after purification. The purification process requires a low-temperature high-speed centrifuge, which requires high equipment costs, and the maximum volume of a single centrifugation is 2L of processing liquid, and the dialysis process is cumbersome. In addition, the cost of the chromatographic column filler is relatively high, and the chromatographic column amplification process is prone to differences. The purification cycle of the experimental group's treatment process is short, it is not limited by high-priced equipment, and the safety and controllability of the process are excellent.
[0193] Table 11. Purification rate and purity of hybrid mouse monoclonal antibodies
[0194]
[0195] The antibodies secreted by the hybridoma cell lines of ascites M002, M011, A032, A065, and E102 projects are MBP-3# (secreting myelin basic protein antibody clone 3), MBP-19# (secreting myelin basic protein antibody clone 19), AFP-6# (secreting alpha-fetoprotein antibody clone 6), AFP-18# (secreting alpha-fetoprotein antibody clone 18), and EB-9# (secreting Epstein-Barr virus antibody clone 9), respectively.
[0196] 5. Application of Monoclonal Antibodies
[0197] The monoclonal antibodies purified above are preferably used as blocking agents in the kit, and can also be used for coated antibodies and enzyme-labeled antibodies. However, the effect of using them as blocking agents is significantly outstanding. Taking the enzyme immunoassay for HBeAg as an example, the evaluation results of the blocking ability of adding clean antibodies are shown in Table 12:
[0198] Table 12. Evaluation of the effect of monoclonal antibody blockers in different processes
[0199] Serum samples No cleaning antibody Control process (octanoic acid ammonium sulfate process) Process of the present invention Serum 261 0.597 0.258 0.026 Serum 397 3.316 1.302 0.621 Serum 724 0.476 0.186 0.04 Serum 0813 0.071 0.029 0.013 Serum 0945 0.213 0.035 0.005 Serum 1289 0.085 0.016 0.003
[0200] Sera 261, 397, 724, 0813, 0945, and 1289 represent different serum samples.
[0201] V. Conclusion
[0202] The hybrid mouse model used in the present invention uses liquid paraffin and pristane to pre-treat its abdominal cavity twice before use. Since pristane and liquid paraffin are immunosuppressants, they can reduce the immunity of mice and reduce the rejection reaction of mice to hybridoma cells. At the same time, they can stimulate mice to produce interleukin 6, which is a growth factor for plasma cells; provide a suitable growth environment for hybridoma cells, which is conducive to the formation of ascites and avoids the phenomenon of no ascites after inoculation; in addition, the present invention uses the preferential domestication of semi-adherent and semi-suspended cells to suspension cell culture, which greatly reduces the tumor formation rate after inoculation into the mouse abdominal cavity, ensuring that the ascites growth rate of the hybrid mouse model is as high as 100%.
[0203] The hybrid mouse model uses 20-22 week old BALB / c mice (SPF grade) in the paternal line and 20-22 week old PT mice (SPF grade) in the maternal line. Due to the higher safety level, only the F1 generation hybrid mouse model obtained by this method can ensure the smooth progress of the experiment. If the paternal line of the hybrid mouse model obtained by the experiment is replaced, the ascites of the relevant monoclonal antibody cannot be prepared.
[0204] The ascites prepared according to the present invention and the purified target protein (monoclonal antibody) can be placed in a -80°C freezer or freeze-dried for long-term storage.
[0205] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing a monoclonal antibody, characterized in that: include: The first-generation mice were obtained by hybridization with BALB / c mice as the father and PT mice as the mother. The abdominal cavity of the mice was pre-treated and then injected with the domesticated hybridoma cell suspension. The mouse ascites was then collected and purified to obtain monoclonal antibodies.
2. The preparation method according to claim 1, characterized in that: The male BALB / c mice are 20 to 22 weeks old; The maternal PT mice were 20 to 22 weeks old.
3. The preparation method according to claim 1 or 2, characterized in that: The pretreatment includes: intraperitoneal injection of paraffin and intraperitone injection of pristane.
4. The preparation method according to any one of claims 1 to 3, characterized in that: The mice were 15 to 16 weeks old when the paraffin was intraperitoneally injected, and the injection volume was 0.8 ml / mouse.
5. The preparation method according to any one of claims 1 to 4, characterized in that: The time of intraperitoneal injection of pristane is 4 to 5 weeks after intraperitoneal injection of paraffin, and the injection volume is 0.8 ml / mouse.
6. The preparation method according to any one of claims 1 to 5, characterized in that: In the hybridoma cell suspension, the density of the hybridoma cells is (6-8)×10 6 Pieces / ml; The amount of the injected acclimated hybridoma cell suspension is 0.5 ml / cell.
7. The preparation method according to any one of claims 1 to 6, characterized in that: The mice are 20 to 22 weeks old when the domesticated hybridoma cells are injected.
8. The preparation method according to any one of claims 1 to 7, characterized in that: The domestication method is shake flask suspension culture, and the parameters of the shake flask suspension culture include: 25-100 amplitude, 50-130r / min, 37°C, and 5% CO2.
9. The monoclonal antibody produced by the method according to any one of claims 1 to 8.
10. A product comprising an adjuvant and the monoclonal antibody according to claim 9.
Citation Information
Patent Citations
Method for improving hybridoma cell antibody secreting capacity through mouse model
CN107459573A
Mouse ascites sensitizer and application thereof
CN115417927A
Monoclonal antibody
EP0179576A2
Anti-human pivka-ii antibody, hybridoma and method for immunological measurement
JP1993284994A
